DOI QR코드

DOI QR Code

Introduction of Recent Hypertension Guidelines

고혈압

  • Lee, Hae-Young (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
  • 이해영 (서울대학교 의과대학 서울대학교병원 순환기내과)
  • Published : 2014.08.01

Abstract

The goal of hypertension treatment is no longer merely controlling blood pressure, but targets overall risk control. Clinicians want guidance on hypertension management using the best scientific evidence available. Here, the recent hypertension guidelines are introduced and compared.

Keywords

References

  1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  2. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014;63:878-885. https://doi.org/10.1161/HYP.0000000000000003
  3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520. https://doi.org/10.1001/jama.2013.284427
  4. Jeong JW. Current guidelines for hypertension control and choice of antihypertensive drugs. Korean J Med 2011;80:280-285.
  5. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572. https://doi.org/10.1001/jama.289.19.2560
  6. Lee SR, Cha MJ, Kang DY, Oh KC, Shin DH, Lee HY. Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey. Int J Cardiol 2013;166:633-639. https://doi.org/10.1016/j.ijcard.2011.11.095
  7. Jee SH, Appel LJ, Suh I, Whelton PK, Kim IS. Prevalence of cardiovascular risk factors in South Korean adults: results from the Korea Medical Insurance Corporation (KMIC) Study. Ann Epidemiol 1998;8:14-21. https://doi.org/10.1016/S1047-2797(97)00131-2
  8. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898. https://doi.org/10.1056/NEJMoa0801369
  9. Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56:196-202. https://doi.org/10.1161/HYPERTENSIONAHA.109.146035
  10. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585. https://doi.org/10.1056/NEJMoa1001286
  11. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998;351:1755-1762. https://doi.org/10.1016/S0140-6736(98)04311-6
  12. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431. https://doi.org/10.1001/jama.288.19.2421
  13. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. 2010;363:918-929.
  14. De Caterina AR, Leone AM. The role of Beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep 2011;13:147-153. https://doi.org/10.1007/s11883-010-0157-9
  15. Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-988. https://doi.org/10.2337/dc07-1768
  16. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. https://doi.org/10.1056/NEJMoa0801317